EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Benzoxaborole-modified azithromycins inhibit translation without inducing ermC expression

Inna A Volynkina iD, Michael O Bortyazh iD, Chih-Wei Chen iD, Andrey G Tereshchenkov iD, Anastasiia O Karakchieva iD, Dmitrii A Lukianov iD, Ekaterina S Komarova iD, Alexey E Tupikin iD, Dmitry A Skvortsov iD, Anna N Tevyashova iD, Alexander S Tikhomirov iD, Vadim N Tashlitsky iD und 5 weitere

Antimicrobial Agents and Chemotherapy · 06.05.2026 · 70 (5)

DOI: 10.1128/aac.01539-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.05.2026. Verfasst von Inna A Volynkina und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia. Hauptthemen laut MEDLINE: Azithromycin, Anti-Bacterial Agents, Escherichia coli, Protein Biosynthesis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, Ministry of Science and Higher Education of the Russian Federation, Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The rapid increase in antimicrobial resistance underscores the urgent need for new antibacterial agents. One promising strategy involves designing novel compounds through targeted chemical modifications of existing antibiotics. Azithromycin (AZI), a widely used macrolide, has served as a versatile scaffold for developing numerous antibacterial candidates. However, the mechanistic consequences of such modifications remain largely unexplored. Here, we characterize the activity and mechanism of action of three AZI-benzoxaborole (AZI-BB) conjugates. We show that these compounds inhibit bacterial translation in vitro and remain active against a model Escherichia coli strain carrying an inducible ermCL-ermC operon, which confers resistance to macrolide antibiotics. Unlike erythromycin, these derivatives, along with AZI itself, exhibit minimal induction of ErmC expression. Structural analysis reveals that the benzoxaborole moiety of AZI-BB2 forms additional interactions with nucleotides C2441 and C2586 of 23S rRNA, likely contributing to premature ribosome stalling at the ermCL regulatory sequence and thereby preventing ErmC expression. Furthermore, high-throughput toeprinting analysis combined with deep sequencing (Toe-seq) demonstrates that AZI-BB2 exhibits reduced sequence specificity for canonical macrolide-sensitive stalling motifs. Altogether, these findings demonstrate that targeted chemical modification of AZI can reshape its context-specific interaction with the ribosome and attenuate the induction of macrolide resistance mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AzithromycinAnti-Bacterial AgentsEscherichia coliProtein BiosynthesisMethyltransferasesMicrobial Sensitivity TestsRNA, Ribosomal, 23SErythromycinMacrolidesGene Expression Regulation, Bacterial

Stichwörter der Autor:innen

antibiotic resistanceazithromycin derivativesbenzoxaborolescontext specificitymacrolidesmechanism of actiontranslation

Substanzen

AzithromycinAnti-Bacterial AgentsRNA, Ribosomal, 23SMethyltransferasesErythromycinMacrolides

Autor:innen und Institutionen

  • Department of Chemistry, Lomonosov Moscow State University, Moscow, Russia.
  • Center for Molecular and Cellular Biology, Moscow, Russia.
  • A.N. Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.
  • Department of Biological Sciences, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Novosibirsk Region, Russia.
  • School of Science, Constructor University, Bremen, Germany.

ORCID-Profile: Inna A Volynkina, Michael O Bortyazh, Chih-Wei Chen, Andrey G Tereshchenkov, Anastasiia O Karakchieva, Dmitrii A Lukianov, Ekaterina S Komarova, Alexey E Tupikin, Dmitry A Skvortsov, Anna N Tevyashova, Alexander S Tikhomirov, Vadim N Tashlitsky, Marsel R Kabilov, Andrey E Shchekotikhin, Olga A Dontsova, Yury S Polikanov, Petr V Sergiev

Förderung

  • NIGMS NIH HHS
  • Ministry of Science and Higher Education of the Russian Federation
  • Russian Science Foundation
  • Illinois State Startup Funds
  • National Institute of General Medical Sciences

Zitieren

APA

Volynkina, I. A., Bortyazh, M. O., Chen, C. W., Tereshchenkov, A. G., Karakchieva, A. O., Lukianov, D. A., Komarova, E. S., Tupikin, A. E., Skvortsov, D. A., Tevyashova, A. N., Tikhomirov, A. S., Tashlitsky, V. N., Kabilov, M. R., Shchekotikhin, A. E., Dontsova, O. A., Polikanov, Y. S., & Sergiev, P. V. (2026). Benzoxaborole-modified azithromycins inhibit translation without inducing ermC expression. Antimicrobial Agents and Chemotherapy, 70(5). https://doi.org/10.1128/aac.01539-25

Vancouver

Volynkina IA, Bortyazh MO, Chen CW, Tereshchenkov AG, Karakchieva AO, Lukianov DA, et al. Benzoxaborole-modified azithromycins inhibit translation without inducing ermC expression. Antimicrobial Agents and Chemotherapy. 2026;70(5). doi:10.1128/aac.01539-25

BibTeX
@article{Volynkina2026,
  author = {Volynkina, Inna A and Bortyazh, Michael O and Chen, Chih-Wei and Tereshchenkov, Andrey G and Karakchieva, Anastasiia O and Lukianov, Dmitrii A and Komarova, Ekaterina S and Tupikin, Alexey E and Skvortsov, Dmitry A and Tevyashova, Anna N and Tikhomirov, Alexander S and Tashlitsky, Vadim N and Kabilov, Marsel R and Shchekotikhin, Andrey E and Dontsova, Olga A and Polikanov, Yury S and Sergiev, Petr V},
  title = {Benzoxaborole-modified azithromycins inhibit translation without inducing ermC expression},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {5},
  doi = {10.1128/aac.01539-25}
}
Kostenlos starten →